Literature DB >> 32739287

Ketamine beyond anesthesia: Antidepressant effects and abuse potential.

Keith A Trujillo1, Sergio D Iñiguez2.   

Abstract

Entities:  

Year:  2020        PMID： 32739287      PMCID： PMC7577378          DOI： 10.1016/j.bbr.2020.112841

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN： 0166-4328            Impact factor:   3.332


× No keyword cloud information.
  45 in total

1.  Phencyclidine and ketamine intoxication: a study of four populations of recreational users.

Authors:  R K Siegel
Journal:  NIDA Res Monogr       Date:  1978-08

2.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

3.  Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice.

Authors:  Israel Garcia-Carachure; Francisco J Flores-Ramirez; Samuel A Castillo; Anapaula Themann; Miguel A Arenivar; Joshua Preciado-Piña; Arturo R Zavala; Mary Kay Lobo; Sergio D Iñiguez
Journal:  Neuropsychopharmacology       Date:  2020-03-12       Impact factor: 7.853

4.  The metaplastic effects of ketamine on sucrose renewal and contextual memory reconsolidation in rats.

Authors:  Alessandro Piva; Lucia Caffino; Laura Padovani; Nicholas Pintori; Francesca Mottarlini; Giuseppe Sferrazza; Giovanna Paolone; Fabio Fumagalli; Cristiano Chiamulera
Journal:  Behav Brain Res       Date:  2019-11-07       Impact factor: 3.332

Review 5.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

6.  Long-lasting effects of repeated ketamine administration in adult and adolescent rats.

Authors:  M L Shawn Bates; Keith A Trujillo
Journal:  Behav Brain Res       Date:  2019-04-26       Impact factor: 3.332

7.  Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.

Authors:  Zhongwei Xiong; Yuko Fujita; Kai Zhang; Yaoyu Pu; Lijia Chang; Min Ma; Jincao Chen; Kenji Hashimoto
Journal:  Behav Brain Res       Date:  2019-04-11       Impact factor: 3.332

8.  Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers.

Authors:  Andrew Ni; F Lee Cantrell; Richard F Clark
Journal:  Am J Emerg Med       Date:  2018-05-03       Impact factor: 2.469

9.  Patterns of use and harms associated with non-medical ketamine use.

Authors:  Paul Dillon; Jan Copeland; Karl Jansen
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

10.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153
View more
  1 in total

1.  Autophagy Induction and Accumulation of Phosphorylated Tau in the Hippocampus and Prefrontal Cortex of Adult C57BL/6 Mice Subjected to Adolescent Fluoxetine Treatment.

Authors:  Jorge A Sierra-Fonseca; Minerva Rodriguez; Anapaula Themann; Omar Lira; Francisco J Flores-Ramirez; Javier Vargas-Medrano; Bharathi S Gadad; Sergio D Iñiguez
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.